Feprazone (DA 2370): Patrick long-term experience in the management of rheumatoid Marion McLeod, arthritis complicated by severe dyspepsia

Summary

Twenty-one patients with rheumatoid arthritis who had been unable to continue with standard non-steroidal anti-inflammatory drugs because of gastro-intestinal intolerance were treated with feprazone (DA 2370) for prolonged periods. Dosage varied from 300 mg. to 800 mg. daily. Mean duration of treatment in 15 patients continuing with the drug was 14.6 months {range 4 to 30 months). Of the 6 patients who were withdrawn, only 2 did so because of gastric intolerance and 2 because of lack of effect. In almost all other instances, improvement occurred in the indices of inflammatory joint activity and there was significant reduction in gastro-intestinal symptomatology over a period of the study. Other side-effects were generally mild and infrequent.

Key Words::

• Feprazone
• anti-inflammatory agents
• arthritis
• rheumatoid